Ralph R. Weichselbaum, MDD.K. Ludwig Professor of Radiation and Cellular OncologyChairman, Department of Radiation and Cellular OncologyDr. Ralph Weichselbaum specializes in the treatment of potentially curative treatment of "oligo" metastasis with radiotherapy. Dr. Weichselbaum's research interests include mechanisms of tumor spread and how radiation therapy and immunotherapy can be used to better treat cancer. He is also studying patterns of gene expression in human tumors that confer resistance to radiotherapy and chemotherapy. Weichselbaum invented a radio-inducible form of gene therapy TNFerade, which is currently in clinical trials. His research has been funded by the National Institutes of Health for more than 35 years. He is also editor of Cancer Medicine, a definitive reference textbook compiled to help oncologists and internists apply scientific principles to clinical practice. Practice LocationThe University of Chicago Medicine
Year Started Practice1975 Board CertificationRadiation Oncology Medical SchoolUniversity of Illinois, Chicago InternshipHighland-Alameda County Hospital, Oakland, CA Residency and FellowshipHarvard Medical School MembershipInstitute of Medicine Language SpokenEnglish Office Phone(773) 702-0817 Office Fax(773) 834-7233 Office Postal AddressRalph Weichselbaum, MD
|
Clinical Interests
Request an appointment online
Read More About Dr. WeichselbaumDr. Weichselbaum and colleagues report that targeted radiation therapy can control cancer in select patients with cancer that has spread (metastatic disease) to only a few sites. Dr. Weichselbaum's research team found that some patients with limited numbers of metastasis can be cured using stereotactic body radiotherapy. Selected PublicationsView a partial list of Dr. Weichselbaum's publications through the National Library of Medicine's PubMed online database. |
